Jump to content

Otsuka Pharmaceutical: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Cleaned up using AutoEd
Line 4: Line 4:
| name = Otsuka Pharmaceutical Co., Ltd.
| name = Otsuka Pharmaceutical Co., Ltd.
| logo = Otsuka Holdings logo.svg
| logo = Otsuka Holdings logo.svg
| caption =
| caption =
| image =
| image =
| image_caption =
| image_caption =
| trading_name =
| trading_name =
| native_name = 大塚製薬株式会社
| native_name = 大塚製薬株式会社
| native_name_lang = ja
| native_name_lang = ja
| romanized_name = Ōtsuka Seiyaku Kabushiki-gaisha
| romanized_name = Ōtsuka Seiyaku Kabushiki-gaisha
| former_name =
| former_name =
| type = [[Public company|Public]] [[Kabushiki gaisha|KK]]
| type = [[Public company|Public]] [[Kabushiki gaisha|KK]]
| traded_as = {{TYO|4578}}<br>[[TOPIX|TOPIX 100 Component]]
| traded_as = {{TYO|4578}}<br>[[TOPIX|TOPIX 100 Component]]
| ISIN =
| ISIN =
| industry = [[Pharmaceutical industry|Pharmaceutical]]
| industry = [[Pharmaceutical industry|Pharmaceutical]]
| genre =
| genre =
| fate =
| fate =
| predecessor =
| predecessor =
| successor =
| successor =
| foundation = 1921 (Originally founded), 1964 (Current corporation)
| foundation = 1921 (Originally founded), 1964 (Current corporation)
| founder = Busaburo Otsuka
| founder = Busaburo Otsuka
| defunct =
| defunct =
| location_city = [[Chiyoda, Tokyo|Chiyoda]], [[Tokyo]]
| location_city = [[Chiyoda, Tokyo|Chiyoda]], [[Tokyo]]
| location_country = [[Japan]]
| location_country = [[Japan]]
| location =
| location =
| coordinate =
| coordinate =
| locations = 69
| locations = 69
| area_served = Worldwide
| area_served = Worldwide
| key_people = Tatsuo Higuchi <small>([[President (corporate title)|President]])</small>
| key_people = Tatsuo Higuchi <small>([[President (corporate title)|President]])</small>
| products =
| products =
| brands =
| brands =
| production =
| production =
| production_year =
| production_year =
| services = <!--サービス-->
| services = <!--サービス-->
| revenue = ¥ 1.74 trillion
| revenue = ¥ 1.74 trillion
Line 39: Line 39:
| operating_income = ¥ 150.32 billion
| operating_income = ¥ 150.32 billion
| income_year = 2022
| income_year = 2022
| net_income =
| net_income =
| net_income_year =
| net_income_year =
| aum =
| aum =
| assets =
| assets =
| assets_year =
| assets_year =
| equity =
| equity =
| equity_year =
| equity_year =
| owner = [[Nomura Trust and Banking]] [[investment trusts]] (11.43%)<br>''and investment trusts managed by other banks''
| owner = [[Nomura Trust and Banking]] [[investment trusts]] (11.43%)<br>''and investment trusts managed by other banks''
| num_employees = 5,634
| num_employees = 5,634
| num_employees_year = 2017
| num_employees_year = 2017
| parent = Otsuka Holdings Co. Ltd
| parent = Otsuka Holdings Co. Ltd
| divisions =
| divisions =
| subsid =
| subsid =
| homepage = [http://www.otsuka.com/en/ otsuka.com]
| homepage = [http://www.otsuka.com/en/ otsuka.com]
| footnotes =
| footnotes =
}}
}}
{{nihongo|'''Otsuka Pharmaceutical Co., Ltd.'''|大塚製薬株式会社|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[Naruto, Tokushima|Naruto]], [[Japan]]. The company was established August 10, 1964.
{{nihongo|'''Otsuka Pharmaceutical Co., Ltd.'''|大塚製薬株式会社|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[Naruto, Tokushima|Naruto]], [[Japan]]. The company was established August 10, 1964.
Line 67: Line 67:
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".<ref>{{Citation |date=January 13, 2012 |publisher=BioSpace |title=Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead |url=http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |access-date=January 15, 2012 |archive-url=https://web.archive.org/web/20160303182456/http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |archive-date=March 3, 2016 |url-status=dead }}</ref> This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.<ref>{{Citation |date=January 13, 2012 |access-date=January 15, 2012|title=UCB and Otsuka to focus collaboration on CNS disorders |publisher=Zenopa|url=http://www.zenopa.com/news/801263654/UCB_and_Otsuka_to_focus_collaboration_on_CNS_disorders }}</ref>
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".<ref>{{Citation |date=January 13, 2012 |publisher=BioSpace |title=Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead |url=http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |access-date=January 15, 2012 |archive-url=https://web.archive.org/web/20160303182456/http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |archive-date=March 3, 2016 |url-status=dead }}</ref> This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.<ref>{{Citation |date=January 13, 2012 |access-date=January 15, 2012|title=UCB and Otsuka to focus collaboration on CNS disorders |publisher=Zenopa|url=http://www.zenopa.com/news/801263654/UCB_and_Otsuka_to_focus_collaboration_on_CNS_disorders }}</ref>


In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref>
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref>


In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.{{cn}}
In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.{{cn}}
Line 74: Line 74:
{{hidden begin|border=1px #aaa solid|title=Otsuka Pharmaceutical Acquisitions|ta1=center}}
{{hidden begin|border=1px #aaa solid|title=Otsuka Pharmaceutical Acquisitions|ta1=center}}
{{Tree list}}
{{Tree list}}
*'''Otsuka Pharmaceutical Co., Ltd'''
* '''Otsuka Pharmaceutical Co., Ltd'''
**[[Ridge Vineyards]] <small>(Acq 1986)</small><ref>{{cite web | url=https://www.otsuka.co.jp/en/company/otsuka-people-talk/13.html | title=Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 &#124; Otsuka People Talk }}</ref>
** [[Ridge Vineyards]] <small>(Acq 1986)</small><ref>{{cite web | url=https://www.otsuka.co.jp/en/company/otsuka-people-talk/13.html | title=Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 &#124; Otsuka People Talk }}</ref>
**[[Crystal Geyser Water Company]] <small>(Acq 1990)</small><ref>[https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library] {{Webarchive|url=https://web.archive.org/web/20190616203733/https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf |date=2019-06-16 }}, ''Otsuka Pharmaceutical''. Retrieved September 21, 2019.</ref>
** [[Crystal Geyser Water Company]] <small>(Acq 1990)</small><ref>[https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library] {{Webarchive|url=https://web.archive.org/web/20190616203733/https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf |date=2019-06-16 }}, ''Otsuka Pharmaceutical''. Retrieved September 21, 2019.</ref>
**[[Astex Pharmaceuticals]] <small>(Merged 2011, Acq 2013)</small><ref>{{cite news| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905| title=Japan's Otsuka to buy U.S. cancer firm Astex for $886 million| first=Tim| last=Kelly| agency=Reuters| date=September 5, 2013 }}</ref>
** [[Astex Pharmaceuticals]] <small>(Merged 2011, Acq 2013)</small><ref>{{cite news| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905| title=Japan's Otsuka to buy U.S. cancer firm Astex for $886 million| first=Tim| last=Kelly| agency=Reuters| date=September 5, 2013 }}</ref>
***Astex Therapeutics Limited
*** Astex Therapeutics Limited
***SuperGen, Inc
*** SuperGen, Inc
**[[Avanir Pharmaceuticals]] <small>(Acq 2014)</small><ref>{{cite web|url=https://dealbook.nytimes.com/2014/12/02/otsuka-of-japan-to-buy-avanir-pharmaceuticals-for-3-5-billion/?module=BlogPost-Title&version=Blog+Main&contentCollection=Mergers+&+Acquisitions&action=Click&pgtype=Blogs&region=Body|title=Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion|first=Jonathan|last=Soble|website=[[The New York Times]]|date=2 December 2014 |access-date=23 April 2018}}</ref>
** [[Avanir Pharmaceuticals]] <small>(Acq 2014)</small><ref>{{cite web|url=https://dealbook.nytimes.com/2014/12/02/otsuka-of-japan-to-buy-avanir-pharmaceuticals-for-3-5-billion/?module=BlogPost-Title&version=Blog+Main&contentCollection=Mergers+&+Acquisitions&action=Click&pgtype=Blogs&region=Body|title=Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion|first=Jonathan|last=Soble|website=[[The New York Times]]|date=2 December 2014 |access-date=23 April 2018}}</ref>
**[[Daiya]] <small>(Acq 2017)</small><ref>{{Cite web|url=https://www.fooddive.com/news/plant-based-food-firm-daiya-bought-for-32597m-by-pharma-company-otsuka/448160/|title=Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka|website=Food Dive}}</ref>
** [[Daiya]] <small>(Acq 2017)</small><ref>{{Cite web|url=https://www.fooddive.com/news/plant-based-food-firm-daiya-bought-for-32597m-by-pharma-company-otsuka/448160/|title=Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka|website=Food Dive}}</ref>
**ReCor Medical, Inc. <small>(Acq 2019)</small><ref>{{Cite web|url=https://www.biospace.com/article/otsuka-medical-devices-otsuka-holdings-and-recor-medical-announce-signing-of-merger-agreement/|title=Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement|website=BioSpace}}</ref>
** ReCor Medical, Inc. <small>(Acq 2019)</small><ref>{{Cite web|url=https://www.biospace.com/article/otsuka-medical-devices-otsuka-holdings-and-recor-medical-announce-signing-of-merger-agreement/|title=Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement|website=BioSpace}}</ref>
**Otsuka America, Inc
** Otsuka America, Inc
***Visterra <small>(Acq 2019)</small><ref>{{Cite web|url=https://www.genengnews.com/topics/drug-discovery/otsuka-to-acquire-visterra-for-430m-adding-to-its-pipeline-and-platforms/|title=Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms|date=July 11, 2018}}</ref>
*** Visterra <small>(Acq 2019)</small><ref>{{Cite web|url=https://www.genengnews.com/topics/drug-discovery/otsuka-to-acquire-visterra-for-430m-adding-to-its-pipeline-and-platforms/|title=Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms|date=July 11, 2018}}</ref>
***Neurovance, Inc <small>(Acq 2017)</small><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref>
*** Neurovance, Inc <small>(Acq 2017)</small><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref>
***Mindset Pharma Inc <small>(Acq 2023)</small>
*** Mindset Pharma Inc <small>(Acq 2023)</small>
{{Tree list/end}}
{{Tree list/end}}
{{hidden end}}
{{hidden end}}
Line 101: Line 101:


==External links==
==External links==
*{{in lang|ja}} [http://www.otsuka.co.jp/ Otsuka Pharmaceutical Company, Limited.]
* {{in lang|ja}} [http://www.otsuka.co.jp/ Otsuka Pharmaceutical Company, Limited.]
*{{in lang|en}} [https://www.otsuka.com/en/ir/library/pdf/2017/2017_a4.pdf Otsuka Integrated Report 2017] (PDF) ({{Webarchive|url=https://web.archive.org/web/20210525104912/https://www.otsuka.com/en/ir/library/pdf/2017/2017_a4.pdf |date=2021-05-25 }})
* {{in lang|en}} [https://www.otsuka.com/en/ir/library/pdf/2017/2017_a4.pdf Otsuka Integrated Report 2017] (PDF) ({{Webarchive|url=https://web.archive.org/web/20210525104912/https://www.otsuka.com/en/ir/library/pdf/2017/2017_a4.pdf |date=2021-05-25 }})


{{TOPIX 100}}
{{TOPIX 100}}

Revision as of 20:19, 25 January 2024

Otsuka Pharmaceutical Co., Ltd.
Native name
大塚製薬株式会社
Ōtsuka Seiyaku Kabushiki-gaisha
Company typePublic KK
TYO: 4578
TOPIX 100 Component
IndustryPharmaceutical
Founded1921 (Originally founded), 1964 (Current corporation)
FounderBusaburo Otsuka
Headquarters
Chiyoda, Tokyo
,
Japan
Number of locations
69
Area served
Worldwide
Key people
Tatsuo Higuchi (President)
Revenue¥ 1.74 trillion (2022)
¥ 150.32 billion (2022)
OwnerNomura Trust and Banking investment trusts (11.43%)
and investment trusts managed by other banks
Number of employees
5,634 (2017)
ParentOtsuka Holdings Co. Ltd
Websiteotsuka.com

Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

History

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company.[1] The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.[1]

Otsuka Pharmaceutical Co. Ltd Holdings

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.[2]

In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.[3]

In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".[4] This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.[5]

In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.[6]

In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.[citation needed]

Acquisition history

Otsuka Pharmaceutical Acquisitions

Products

Products of Otsuka Pharmaceutical

References

  1. ^ a b Fujita, Junko; Slodkowski, Antoni (December 16, 2010). Layne, Nathan (ed.). "Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1". Reuters. Archived from the original on March 4, 2012. Retrieved January 15, 2012.
  2. ^ "Tokushima Vortis". 15 January 2020. Retrieved October 30, 2020.
  3. ^ "Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A." otsuka.co.jp. May 28, 2008. Retrieved October 30, 2020.
  4. ^ Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead, BioSpace, January 13, 2012, archived from the original on March 3, 2016, retrieved January 15, 2012
  5. ^ UCB and Otsuka to focus collaboration on CNS disorders, Zenopa, January 13, 2012, retrieved January 15, 2012
  6. ^ "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. 3 March 2017. Retrieved 23 April 2018.
  7. ^ "Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 | Otsuka People Talk".
  8. ^ Otsuka.com Library Archived 2019-06-16 at the Wayback Machine, Otsuka Pharmaceutical. Retrieved September 21, 2019.
  9. ^ Kelly, Tim (September 5, 2013). "Japan's Otsuka to buy U.S. cancer firm Astex for $886 million". Reuters.
  10. ^ Soble, Jonathan (2 December 2014). "Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion". The New York Times. Retrieved 23 April 2018.
  11. ^ "Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka". Food Dive.
  12. ^ "Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement". BioSpace.
  13. ^ "Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms". July 11, 2018.
  14. ^ "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. 3 March 2017. Retrieved 23 April 2018.
  15. ^ "Aripiprazole". AdisInsight. Retrieved 4 June 2017.
  16. ^ Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Otsuka_Pharmaceutical&oldid=1199055472"